




Drug Discovery in Infectious Diseases  
Series Editor Paul M. Selzer

Volume 5

# Protein Phosphorylation in Parasites

Novel Targets for Antiparasitic Intervention

Edited by Christian Doerig, Gerald Späth,  
and Martin Wiese




WILEY Blackwell

*Edited by Christian Doerig, Gerald Späth, and Martin Wiese*

## **Protein Phosphorylation in Parasites**

*Novel Targets for Antiparasitic Intervention*



**WILEY Blackwell**

## The Editors

### Volume Editors:

#### **Prof. Dr. Christian Doerig**

Monash University  
Department of Microbiology  
Wellington Road Clayton  
Building 76  
Victoria 3800  
Australia  
christian.doerig@monash.edu

#### **Dr. Gerald Späth**

Institut Pasteur  
Department of Parasitology and Mycology  
Rue du Dr. Roux 25  
75015 Paris  
France  
gerald.spaeth@pasteur.fr

#### **Dr. Martin Wiese**

University of Strathclyde  
Institute of Pharmacy and Biomedicine  
Cathedral Street 161  
G4 0RE Glasgow  
United Kingdom  
martin.wiese@strath.ac.uk

### Series Editor:

#### **Prof. Dr. Paul M. Selzer**

MSD Animal Health Innovation GmbH  
Zur Propstei  
55270 Schwabenheim  
Germany  
paul.selzer@msd.de

### Cover legend

See page XIII

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty can be created or extended by sales representatives or written sales materials. The Advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

**Library of Congress Card No.:** applied for

### **British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

### **Bibliographic information published by the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical, and Medical business with Blackwell Publishing.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Print ISBN:** 978-3-527-33235-9

**ePDF ISBN:** 978-3-527-67539-5

**ePub ISBN:** 978-3-527-67537-1

**Mobi ISBN:** 978-3-527-67538-8

**oBook ISBN:** 978-3-527-67540-1

**Cover Design** Adam-Design, Weinheim, Germany

**Typesetting** Thomson Digital, Noida, India

**Printing and Binding** Markono Print Media Pte Ltd, Singapore

Printed on acid-free paper

*Edited by*  
*Christian Doerig, Gerald Späth, and Martin Wiese*

**Protein Phosphorylation in Parasites**

## *Titles of the Series "Drug Discovery in Infectious Diseases"*

Selzer, P.M. (ed.)

### **Antiparasitic and Antibacterial Drug Discovery From Molecular Targets to Drug Candidates**

2009

Print ISBN: 978-3-527-32327-2, also available  
in Adobe PDF format ISBN: 978-3-527-62682-3

Becker, K. (ed.)

### **Apicomplexan Parasites Molecular Approaches toward Targeted Drug Development**

2011

Print ISBN: 978-3-527-32731-7, also available  
as digital format

Caffrey, C.R. (ed.)

### **Parasitic Helminths Targets, Screens, Drugs and Vaccines**

2012

Print ISBN: 978-3-527-33059-1, also available  
as digital format

Jäger, T., Koch, O., Flohé, L. (eds.)

### **Trypanosomatid Diseases Molecular Routes to Drug Discovery**

2013

Print ISBN: 978-3-527-33255-7, also available  
as digital format

## *Forthcoming Topics of the Series*

Gottfried Unden, Eckard Thines, Anja Schöffler (eds.) Antiinfectives  
Christian Doerig, Gordon Langsley, Pietro Alano (eds.) Malaria Signaling

## *Related Titles*

Li, R., Stafford, J.A. (eds.)

### **Kinase Inhibitor Drugs**

2009

Print ISBN: 978-0-470-27829-1, also available  
as digital format

Klebl, B., Müller, G., Hamacher, M. (eds.)

### **Protein Kinases as Drug Targets**

2011

Print ISBN: 978-3-527-31811-7, also available  
as digital format

Ghosh, A.K. (ed.)

### **Aspartic Acid Proteases as Therapeutic Targets**

2010

Print ISBN: 978-3-527-31811-7, also available  
as digital format

Smit, M.J., Lira, S.A., Leurs, R. (eds.)

### **Chemokine Receptors as Drug Targets**

2011

Print ISBN: 978-3-527-32118-6, also available  
as digital format



## Foreword: Protein Kinases in Parasites

Today, despite the fact that this is not obvious to the vast majority of the people leaving in industrialized countries, a large part of the world is still massively suffering and dying from parasitic diseases as a result of the lack of efficacious and/or affordable treatments. Each year 30,000 people pass away due to human African Trypanosomiasis (HAT or African sleeping sickness), a disease caused by the parasite *Trypanosoma brucei* spp. Available treatments for this disease are poor, with unacceptable efficacy and safety profiles, particularly in the late phase of the infection when the parasite has invaded the central nervous system. In South and Central America, *Trypanosoma cruzi* is the infectious agent of Chagas' disease (American Trypanosomiasis) which represents the most important parasitic infection in this part of the world. It is affecting more than 10 million people, with about 100 million people at risk. Leishmaniasis is due to the infection by protozoa of the genus *Leishmania* and is affecting more than 10 million people worldwide. These parasites live in the alimentary tract of blood-sucking sand flies, and as nonflagellate intracellular forms mostly within the macrophages of mammalian hosts. The severity of the disease is ranging from cutaneous and/or mucosal to visceral infection. Malaria occurs following infection by *Plasmodium* spp. and is the most prevalent parasitic disease, affecting more than 250 million of people per year and still responsible for almost a million deaths, the vast majority of which impacting children below 5 years. Not only unicellular parasites bear a huge impact on global public health: parasitic helminths (worms), such as *Schistosoma* spp., also represent a serious public health problem, mostly in the developing world. In view of such a dramatic situation, more than ever, it is crucial that the entire scientific community in basic research and industries develops all possible strategies leading to an arsenal of therapeutic weapons that will efficiently treat patients and eradicate these diseases. Among possible drug targets, enzymes that modulate the level of phosphorylation of parasite and host proteins such as protein kinases (PKs) and protein phosphatases are interesting candidates.

First, the kinomes of parasites like kinetoplastids and apicomplexans could reveal promising taxon-specific drug targets. Indeed, signalling pathways are well known to allow any organism to adapt to its environment by coordinating intracellular processes. Bioinformatics approaches revealed a total of 176 PKs in *T. brucei*, 190 in

*T. cruzi* and 199 in *L. major*. Compared to trypanosomatids, the human kinome contains 3 times more protein kinases while the size of the *Plasmodium* kinome is only about half that of trypanosomatids. Trypanosomatids and *Plasmodium* do not contain receptor-linked tyrosine kinases, but possess divergent kinases with no orthologues in the mammalian kinome (Ward P, Equinet L, Packer J, Doerig C. 2004. BMC Genomics; Parsons, M, Worthey E, Ward P, Mottram J. 2005. BMC Genomics). The fact that trypanosomatids exhibit a large set of PKs, covering approximately 2% of each genome, suggests that phosphorylation may play a key role in the biology of most parasites.

Despite differences in kinome sizes and composition from one parasite to another, major signalling pathways and functions are conserved. Motility, for instance, is an essential attribute that allows some parasites finding their target cells in human hosts and/or arthropod vectors. In apicomplexans, this key driving force depends on a unique component whereby adhesins contained in the micronemes are released onto the parasite apical extremity and translocated to the posterior end of the cell, thus propelling the parasite forward. In *Toxoplasma gondii*, Calcium-dependent protein kinase 1 (TgCDPK1) is an essential regulator of calcium-dependent exocytosis and this could well be the case in most of the opportunistic human parasites. Recently, the phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2 $\alpha$ ) was described elevated in dormant forms of apicomplexan parasites such as *Plasmodium* spp. and *Toxoplasma gondii*. (Zhang M. *et al.*, Eukaryotic Cell, 2013).

Kinases have been shown to be essential for survival of parasites in their mammalian hosts. Nevertheless, a parasite kinase-specific small molecule inhibitor still awaits to be identified and the question whether drugging the parasite kinome is more a dream or a reality begs for an answer. In complex parasite life cycles such as that of *Plasmodium*, most of the key developmental forms of the parasite such as sexual and liver stages rely on protein kinase-mediated regulations as highlighted by C. Doerig (Nat. Chem. Biol.) commenting the work of Kato *et al.* who has demonstrated that PfCDPK1 plays a key role in asexual blood stage egress. Considering the 3-dimensional structure of protein kinases, there are increasing evidences that the ATP-binding pocket represents a druggable site. Specific kinomes like the one of *Plasmodium* display sufficient specificity, compared to the human one, to represent a potentially fertile source of novel targets. Interestingly, the counteracting biochemical reactions driven by *Plasmodium* phosphatases are similarly specific enough to envisage drug discovery programs targeting molecular events that are modulated by these enzymes (Wilkes and Doerig BMC genomics 2008).

Since helminths are Metazoan and have therefore a kinome that is very similar to that of their hosts, it is unlikely that highly selective targets will be identified. However, the kinome still remains an attractive target in this case to: precisely because of similarities between the helminthic and human kinomes, "piggy-back" approaches exploiting the wealth of resources devoted to targeting human kinases in the context of diseases such as cancer and neurodegenerative diseases is an attractive option as a strategy to combat diseases caused by worms.

Last but not least, the host-parasite interface might well be a target of choice to avoid induction of drug resistance and spreading. *Plasmodium* infection of host cells takes advantage of the plasticity of this parasite and the different forms produced along its complex life cycle. For instance during the infection of human hepatocytes (liver stage of *Plasmodium*'s life cycle), not only part of the parasite kinome is solicited but some human protein kinases in liver cells such as MET, PRKWNK1, SGK2, STK35 and PKC $\zeta$  seem to be crucial to *Plasmodium* sporozoite invasion mechanism and differentiation/growth (Prudêncio M. *et al.*, 2008, PLoS Pathogens). Evidence is emerging that even in the erythrocyte, host signalling pathways are activated and required for parasite survival (Sicard *et al* 2011). Host protein kinases such as MEKs and downstream MAPKs may play a key role in the host immune response to *Plasmodium*. Indeed, these protein kinases have been shown to regulate the production of pro-inflammatory cytokines produced in response to specific markers of various infectious agents that may modulate the specificity and effectiveness of adaptive immunity. Thus, small molecules could be used as immunomodulatory tools to control pathogen infections and resulting diseases by regulating specific host protein kinases. (Zhu J. *et al.*, 2009, J. Biol. Chem.).

In the present book, the bioinformatics approach leading to the study of parasite kinomes and phosphatomes will be described and followed by chapters addressing the functional analysis of some of the key enzymes. The potential roles of host cell kinome and phosphatome will be discussed. Finally, opportunities for drug discovery programs targeting parasite protein kinases and phosphatases will be explored in protozoan and helminthic parasites alike. There is no doubt that the holistic view described in this book will contribute to the future success of new efficacious and affordable therapeutics to treat the world population severely impacted by parasitic diseases.

Geneva, July 2013

Didier Leroy



## Preface

Diseases caused by eukaryotic pathogens have been a scourge of human populations ever since the emergence of our species. Many of the major lineages of eukaryotes, from Excavata (*Giardia*), through Discicristata (*Trypanosoma*, *Leishmania*), Amoebozoa (*Entamoeba*) and Alveolata (*Plasmodium*, *Toxoplasma*, *Eimeria*), to Opisthokonta (metazoans, fungi), include species that have adapted to a parasitic lifestyle and have co-evolved with their hosts in the lineage that led to *Homo sapiens*. The burden imposed by parasitic diseases is disproportionately large in the poorest nations. While there has been immense progress in controlling some of these diseases in the second half of the XXth century, notably through the use of specific drugs, the global picture remains very gloomy: first, pathogens have responded to novel treatments by developing resistance against the drugs; thus, for example, that wonder antimalarial drug, chloroquine, has now become ineffective in a majority of malaria-affected countries. Even the latest generation of antimalarial drugs, based on artemisinin, shows signs of losing efficacy in some parts of the world. Second, many of these diseases have remained grossly neglected in terms of investment in research and development of novel control agents, largely because of the poor marketing prospects such agents would offer. Clearly, a renewed effort is urgently needed to address this global issue. Fortunately, awareness has increased in the last decade, which has led to an increase of funding from public institutions such as the European Commission and the research councils and agencies of many governments, as well as private bodies such as the Bill & Melinda Gates foundation. Furthermore, new organisational tools now exist to fund such research; for example, the Medicines for Malaria Venture (MMV, [www.mmv.org](http://www.mmv.org)), a Public-Private Partnership based in Geneva, and the Drugs for Neglected Diseases initiative (DNDi, [www.dndi.org](http://www.dndi.org)), have already had a tangible impact in this area. To eventually bring parasitic diseases under effective control, it is crucial that existing funding for fundamental research on eukaryotic pathogens is maintained and expanded, so as to prime the drug development pipeline. A high priority on the agenda is to develop control agents with un-tapped mechanisms of action.

Protein phosphorylation is an enormously important phenomenon in the biology of eukaryotic cells, where it regulates essentially all complex processes. This fundamental role has singled out protein kinases as potential targets for anticancer

agents, and indeed, a number of protein kinase inhibitors have reached the market in this context.

Could protein kinases represent targets for the treatment of parasitic diseases as well? A group of about 25 researchers interested in this idea convened in Paris in 2001, at the first EU-COST-funded meeting on "Protein kinases of eukaryotic parasites". This forum has reconvened in Glasgow in 2005, and in Lausanne in 2010. By then, the attending community had grown to 80 people, and significant progress had been achieved in (i) our fundamental understanding of the complement of parasite protein kinases and protein phosphatases (kinome and phosphatome) and the function of these enzymes in the biology of the parasites, and (ii) the identification of specific kinase targets in many eukaryotic parasites, and, in a few cases, of parasite kinase inhibitors. It was also emerging that the phosphorylation machinery in the host was playing a crucial role in parasite survival and development, suggesting that kinase inhibitors developed against cancer might be re-positioned for the treatment of parasitic diseases.

The present book is an outcome of the 2010 meeting in Lausanne, and offers a written and updated version of some of the highlights that were presented there. It covers bio-informatics analyses of the kinomes and phosphatomes of selected eukaryotic parasites, recent advances in our fundamental understanding of the biology of selected kinases and phosphatases (inclusive of host signalling elements), and finally the state-of-the-art with respect to anti-parasitic drug discovery efforts targeting protein kinases.

We consider protein kinases offer huge potential for the development of urgently needed control agents against devastating diseases caused by eukaryotic parasites. This will happen only if the research community embraces the idea and constitutes compelling supporting data, so that policymakers and industrial partners can be convinced that there would be a significant return on investment in terms of impact on global public health. The purpose of this book is therefore to stimulate interest of established researchers and students in this topic, which offers a combination of both fascinating biology and potential tangible impact.

The Editors are aware of the significant additional commitment that engaging into the writing of a chapter represents in the busy life of research scientists, and are therefore very grateful to all authors for their timely contributions. We are indebted to the series editor, Dr. Paul M. Selzer of MSD Animal Health Innovation GmbH, for his constant encouragements and active involvement in the preparation of this volume, and to Anne du Guerny, Project Editor at Wiley Blackwell, for her patience and excellent support throughout the publication process.

Melbourne, Paris, and Glasgow  
September 2013

*Christian Doerig, Gerald Späth,  
and Martin Wiese*

## Cover Legend

The cover is composed of several illustrations coming from or being related to the articles in this volume. The underlying phylogenetic tree illustrates the evolutionary relationships among eukaryotic species, including model organisms and protozoan pathogens, selected across all eukaryotic supergroups (courtesy of D. Miranda-Saavedra, see chapter 1 for details). The protein structure shows the homology model of EtCRK2 a CDK2-like protein of *Eimeria tenella* with ATP docked into the ATP binding pocket. The protein is shown as ribbons, while ATP is depicted in ball-and-stick representation with atoms colored according to the CPK model (courtesy of R. J. Marhöfer, see chapter 15 for details). The black matrix panel shows fluorescence microscopy images of different parasites. The top row of the panel shows an intra-erythrocytic *Plasmodium falciparum* schizont. The mitotic regulator Aurora kinase 3 is labeled in green, the *Plasmodium* homologue of centrosome protein Centrin-3 is labeled in red and the parasite DNA is stained in blue (courtesy of T. Carvalho, see chapter 1 and 13 for details). The middle row of the panel shows immunofluorescent staining of *Trypanosoma brucei* bloodstream forms. PKA-like kinase substrates are labeled in red, the paraflagellar rod protein in green as reference for the flagellum, and nuclear and kinetoplast DNA are stained blue with DAPI (courtesy of S. Bachmaier and M. Boshart, see chapter 5 for details). The lower row, from left to right, shows in the 1<sup>st</sup> image, eggs of *Schistosoma mansoni* purified from livers of infected hosts. Due to tyrosine-rich eggshell precursor proteins, which are fused via quinone tanning during eggshell synthesis, green and red auto-fluorescence is observed by fluorescence microscopy (courtesy of C. G. Grevelding, see chapter 16 for details). The 2<sup>nd</sup> image shows several human fibroblast cells with large blue nuclei massively infected with a transgenic strain of *T. gondii* tachyzoites visualized by small blue nuclei expressing GFP in its single mitochondrion. Cellular lipid bodies are stained red with Oil red O (courtesy of F. Seeber, Robert Koch Institute, Berlin, Germany). The 3<sup>rd</sup> image shows a section of a *Schistosoma mansoni* male worm labeled with anti-*S. mansoni* Insulin Receptor 1 antibodies. The antibody was localized at the basal membrane of the tegument, in muscles and in intestinal epithelium of worms (courtesy of C. Dissous, see chapter 16 for details). The 4<sup>th</sup> image shows an *Echinococcus multilocularis* protoscolex with DAPI/phalloidin staining (courtesy of K. Brehm, see chapter 17 for details).

## List of Contributors

### ***Roman Affentranger***

Douglas Connect  
Baermeggenweg 14  
4314 Zeiningen  
Switzerland

### ***Merhnaz Amani***

Structural Genomics Consortium  
MaRS South Tower, 7th Floor  
101 College Street  
Toronto, Ontario  
Canada

### ***Alexandra V. Andreeva\****

University of Illinois at Chicago  
Department of Pharmacology  
909 S. Wolcott Ave  
Chicago, IL 60612  
USA  
alexandravandreeva@gmail.com

### ***Gustavo Arrizabalaga***

Indiana University School of  
Medicine  
Departments of Pharmacology &  
Toxicology, Microbiology &  
Immunology  
635 Barnhill Drive, MS A-503  
Indianapolis, IN 46202  
USA

### ***Jennifer D. Artz***

Structural Genomics Consortium  
MaRS South Tower, 7th Floor  
101 College Street  
Toronto, Ontario  
Canada

### ***Mrigya Babuta***

Jawaharlal Nehru University  
School of Life Sciences  
New Delhi, 110067  
India

### ***Sabine Bachmaier***

Ludwig-Maximilians-Universität  
München  
Fakultät für Biologie, Genetik  
Biozentrum  
Grosshadernerstr. 2-4  
82152 Planegg-Martinsried  
Germany

### ***Svenja Beckmann***

Justus-Liebig-University  
Institute for Parasitology  
Rudolf-Buchheim-Str. 2  
35392 Giessen  
Germany

\*Corresponding Author



**Corinna Benz**

University of South Bohemia  
Institute of Parasitology  
Biology Centre and Faculty of  
Sciences  
Česká Budějovice  
Czech Republic

**Alok Bhattacharya\***

Jawaharlal Nehru University  
School of Life Sciences  
New Delhi, 110067  
India  
alok.bhattacharya@gmail.com;  
alok0200@mail.jnu.ac.in

**Sudha Bhattacharya**

Jawaharlal Nehru University  
School of Environmental Sciences  
New Delhi, 110067  
India

**Ira J. Blader\***

University at Buffalo  
Department of Microbiology and  
Immunology  
138 Farber Hall  
Buffalo, NY 14214  
USA  
iblader@buffalo.edu

**Michael Boshart\***

Ludwig-Maximilians-Universität  
München  
Fakultät für Biologie, Genetik  
Biozentrum  
Grosshadernerstr. 2-4  
82152 Planegg-Martinsried  
Germany  
boshart@lmu.de

**Klaus Brehm\***

University of Würzburg  
Institute of Hygiene and  
Microbiology  
Josef-Schneider-Strasse 2  
97080 Würzburg  
Germany  
kbrehm@hygiene.uni-wuerzburg.de

**James R. Brown**

GlaxoSmithKline  
Computational Biology  
Quantitative Sciences, R&D  
1250 South Collegeville Road, UP1230  
Collegeville, PA 19426-0989  
USA

**Sharon D. Bryant**

Inte:Ligand Software Development &  
Consulting GmbH  
Mariahilferstrasse 74B/11  
1070 Vienna  
Austria

**Christin Buro**

Justus-Liebig-University  
Institute for Parasitology  
Rudolf-Buchheim-Str. 2  
35392 Giessen  
Germany

**Alessandro Contini**

Università degli Studi di Milano  
Dipartimento di Scienze  
Farmaceutiche – Sezione di Chimica  
Organica “A. Marchesini”  
Via Venezian 21  
20133 Milan  
Italy



**Hugo Gutierrez de Teran**

Uppsala University  
Department of Cell and Molecular  
Biology  
BMC  
754 29 Uppsala  
Sweden

**Colette Dissous\***

Inserm U1019  
CNRS UMR 8204  
Center for Infection and Immunity of  
Lille (CIIL)  
Institut Pasteur de Lille  
1, rue du Prof. Calmette  
59019 Lille  
France  
Colette.dissous@pasteur-lille.fr

**Dirk Dobbelaere**

University of Bern  
Molecular Pathobiology  
Vetsuisse Faculty  
3012 Bern  
Switzerland

**Christian Doerig**

Monash University  
Department of Microbiology  
Wellington Road  
Building 76  
Clayton, Victoria 3800  
Australia

**David Drewry**

GlaxoSmithKline  
Department of Chemical Biology  
20 T. W. Alexander Drive  
Research Triangle Park  
Durham, NC 27709  
USA

**Francisco-Javier Gamo**

GlaxoSmithKline  
Tres Cantos Medicines Development  
Campus  
Severo Ochoa 2  
28760 Tres Cantos  
Spain

**Jose F. Garcia-Bustos\***

Monash University  
Department of Microbiology  
Clayton, Victoria 3800  
Australia  
jose.garcia-bustos@monash.edu

**Daniel E. Goldberg\***

Washington University in St Louis  
Departments of Medicine and  
Molecular Microbiology  
Howard Hughes Medical Institute  
660 S. Euclid Ave  
St Louis, MO 63110  
USA  
goldberg@borcim.wustl.edu

**Nadège Gougnard**

Institut Pasteur de Lille  
Center for Infection and Immunity  
of Lille (CIIL)  
Inserm U1019  
CNRS UMR 8204  
59019 Lille  
France

**Christoph G. Grevelding**

Justus-Liebig-University  
Institute for Parasitology  
Rudolf-Buchheim-Str. 2  
35392 Giessen  
Germany

**Tansy C. Hammarton\***

University of Glasgow  
College of Medical, Veterinary and  
Life Sciences  
Institute of Infection, Immunity &  
Inflammation  
120 University Place  
Glasgow G12 8QQ  
UK  
Tansy.Hammarton@glasgow.ac.uk

**Barry Hardy\***

Douglas Connect  
Baermeggenweg 14  
4314 Zeiningen  
Switzerland  
Barry.Hardy@douglasconnect.com

**Tanya Hills**

Structural Genomics Consortium  
MaRS South Tower, 7th Floor  
101 College Street  
Toronto, Ontario  
Canada

**Raymond Hui\***

Structural Genomics Consortium  
MaRS South Tower, 7th Floor  
101 College Street  
Toronto, Ontario  
Canada  
Raymond.hui@utoronto.ca

**Natarajan Kannan**

University of Georgia  
Institute of Bioinformatics  
Davison Life Sciences Bldg  
120 Green Street  
Athens, GA 30602  
USA

and

University of Georgia  
Department of Biochemistry and  
Molecular Biology  
B122 Life Sciences Bldg  
Athens, GA 30602  
USA

**Mikhail A. Kutuzov\***

University of Illinois at Chicago  
Department of Pharmacology  
909 S. Wolcott Ave  
Chicago, IL 60612  
USA  
m.kutuzov@usa.net

**Didier Leroy\***

Director Drug Discovery  
Medicines for Malaria Venture  
Rte de Pre Bois 20, 1215  
Geneva  
leroyd@mmv.org

**Silke Leutner**

Justus-Liebig-University  
Institute for Parasitology  
Rudolf-Buchheim-Str. 2  
35392 Giessen  
Germany

**Linda. Y. Lin**

Structural Genomics Consortium  
MaRS South Tower, 7th Floor  
101 College Street  
Toronto, Ontario  
Canada

**Isabelle Lucet**

Monash University  
Department of Microbiology  
Wellington Road  
Building 76  
Clayton, Victoria 3800  
Australia

**Dustin J. Maly**

University of Washington  
Department of Chemistry  
Chemistry Building  
Seattle, WA 98195  
USA

**Richard J. Marhöfer**

MSD Animal Health Innovation  
GmbH  
Zur Propstei  
55270 Schwabenheim  
Germany

**Keith R. Matthews**

University of Edinburgh  
School of Biological Sciences  
Institute of Immunology and  
Infection Research  
Centre for Immunity, Infection and  
Evolution  
King's Building, West Mains Road  
Edinburgh EH9 3JT  
UK

**Ethan A. Merritt**

University of Washington  
Department of Biochemistry  
1959 NE Pacific Street  
Health Sciences Building  
Seattle, WA 98195  
USA

**Diego Miranda-Saavedra\***

Institute of Cellular Medicine  
Newcastle University Medical School  
Framlington Place  
Newcastle upon Tyne NE2 4HH  
UK  
diego@ifrec.osaka-u.ac.jp

**Jeremy C. Mottram**

University of Glasgow  
College of Medical, Veterinary and  
Life Sciences  
Institute of Infection, Immunity and  
Inflammation  
Wellcome Trust Centre for Molecular  
Parasitology  
120 University Place  
Glasgow G12 8TA  
UK

**Mirela Neculai**

Structural Genomics Consortium  
MaRS South Tower, 7th Floor  
101 College Street  
Toronto, Ontario  
Canada

**Sandra Nelson**

Chief Technology Officer  
PHD Diagnostics, LLC  
632 Russell Street  
Covington, Kentucky 41011  
USA

**Victor Nussenzweig\***

NYU Langone Medical Center  
Department of Pathology  
550 1st Ave  
New York, NY 10016  
USA  
Victor.Nussenzweig@nyumc.org

**Kayode K. Ojo**

University of Washington  
Department of Medicine  
Division of Allergy and Infectious  
Diseases  
750 Republican Street  
Seattle, WA 98109  
USA

***Maresh Kumar Padwal***

National Centre for Cell Science  
Ganeshkhind  
Pune 411007  
India

***Ruben Papoian***

University of Cincinnati  
Drug Discovery Center  
2180 East Galbraith Road  
Cincinnati, OH 45237  
USA

***Bhaskar Saha\****

National Centre for Cell Science  
Ganeshkhind  
Pune 411007  
India  
sahab@nccs.res.in

***Uddipan Sarma***

National Centre for Cell Science  
Ganeshkhind  
Pune 411007  
India

***William L. Seibel***

University of Cincinnati  
Drug Discovery Center  
Compound Library and  
Cheminformatics  
2180 E. Galbraith Road  
Cincinnati, OH 45237  
USA

***Paul M. Selzer\****

MSD Animal Health Innovation  
GmbH  
Zur Propstei  
55270 Schwabenheim  
Germany  
paul.selzer@msd.de

and

University of Glasgow  
College of Medical, Veterinary and  
Life Sciences  
Institute of Infection, Immunity and  
Inflammation  
Wellcome Trust Centre for Molecular  
Parasitology  
120 University Place  
Glasgow G12 8TA  
UK

and

University of Tübingen  
Interfaculty Institute of Biochemistry  
Hoppe-Seyler-Str. 4  
72076 Tübingen  
Germany

***Somlata***

Jawaharlal Nehru University  
School of Life Sciences  
New Delhi, 110067  
India

***Jeff Spitzner***

Amperand, Ltd.  
311 Kendall PL  
Columbus, OH 43205  
USA

***Raki Sudan***

National Centre for Cell Science  
Ganeshkhind  
Pune 411007  
India